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 Abstract: A growing body of preclinical evidence indicates that certain cannabinoids, including 
cannabidiol (CBD) and synthetic derivatives, may play a role in the myelinating processes and are 
promising small molecules to be developed as drug candidates for management of demyelinating 
diseases such as multiple sclerosis (MS), stroke and traumatic brain injury (TBI), which are three of 
the most prevalent demyelinating disorders. Thanks to the properties described for CBD and its 
interesting profile in humans, both the phytocannabinoid and derivatives could be considered as 
potential candidates for clinical use. In this review we will summarize current advances in the use 
of CBD and other cannabinoids as future potential treatments. While new research is accelerating 
the process for the generation of novel drug candidates and identification of druggable targets, the 
collaboration of key players such as basic researchers, clinicians and pharmaceutical companies is 
required to bring novel therapies to the patients. 
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1. Introduction 
Cannabis sativa, which contains about 545 natural compounds of different chemical 
structures known as cannabinoids, and its use for medicinal purposes, is centuries old [1]. 
The contemporary history of use of medical cannabis begins in the 19th century when an 
Irish physician, William Brooke O’Shaughnessy, introduced the cannabis plant into West-
ern medicine for its analgesic, anti-inflammatory and anticonvulsant properties [2]. The 
most advanced characterization of different compounds extracted from the cannabis 
plant, termed phytocannabinoids, was undertaken during 1960s by the Israeli researcher 
Dr. Ralph Mechoulam, whose group isolated and reported among others on the chiral 
cannabidiol [3] and the psychotropic Δ9-tetrahydrocannabinol (Δ9-THC), two of the main 
bioactive compounds in the plant [4,5]. 
In 1985, the Food and Drug Administration (FDA) approved the first two canna-
binoid derivatives for clinical use named dronabinol and nabilone. Dronabinol contains 
the trans isomer of Δ9-THC (synthetically derived) dosed in a gelatin capsule. This drug 
was approved for two indications: (1) chemotherapy-induced nausea and vomiting; and 
(2) anorexia in acquired immunodeficiency syndrome (AIDS) patients [6]. The second, 
nabilone, is a synthetic cannabinoid that mimics the activity of Δ9-THC. This drug was 
approved by the FDA to treat chemotherapy-induced nausea [7]. Both drugs are available 
only as oral capsules. In 2005, the authorization of Sativex, a mixture of Δ9-THC and CBD 
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indicated to treat pain and spasticity in MS, supposed a milestone in cannabinoids re-
search [7,8]. Furthermore, cannabidiol oral solution named Epidiolex, which presents ben-
eficial effects for treatment of severe childhood epilepsy, has been recently approved by 
the FDA as a non-controlled substance.  
Considerable interest in CBD is emerging due to its beneficial antiepileptic [8], neu-
roprotective in hypoxia-ischemia [9], anxiolytic, antipsychotic [10], anti-inflammatory [11] 
and anticancer properties [12], among others (Table 1). In the past, CBD has received less 
attention as a potential drug candidate than Δ9-THC although it has been commonly used 
in cannabis-based formulations.  
Table 1. Therapeutic potential of CBD, analogs, and derivatives. 








Mecha et al., 2012 [13] 
Burstein et al., 2015 [11] 
Mori et al., 2017 [9] 
Kis et al., 2019 [12] 
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Pellati et al., 2018 [14] 
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Autism spectrum disorder 
Zamberletti et al., 2019 [16] 
Morano et al., 2020 [17] 
 
H2-CBD Inflammation 
Ben-Shabat et al., 2006 [18] 
 
H4-CBD Inflammation 
Ben-Shabat et al., 2006 [18] 
 
HU-446 Inflammation 
Kozela et al., 2016 [19] 
 
HU-465 Inflammation 







Burstein et al., 2015 [11] 





Sumariwalla et al., 2004 [21] 
 
HU-410 Inflammation 
Mechoulam et al., 2008 [22] 
 
HU-427 Inflammation 
Mechoulam et al., 2008 [22] 
 
HU-432 Inflammation 
Mechoulam et al., 2008 [22] 
 
HU-331 Cancer 







Del Rio et al., 2016 [24] 
Navarrete et al., 2018 [25] 
García-Martin et al., 2018 [26] 
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Remyelination García-Martin et al., 2019 [27] 
Navarrete et al., 2020 [28] 
Now, due to its beneficial properties, the business surrounding the use of CBD in 
different products is increasing. In addition, CBD scaffolds have attracted increasing con-
sideration for medicinal chemists. Therefore, CBD constitutes one of the most studied can-
nabinoids in neurodegenerative and demyelinating diseases where CBD has shown ben-
efits in preclinical studies, warranting further investigation.  
2. Cannabidiol: General Pharmacology and Therapeutic Profile 
The understanding of cannabinoid pharmacology is continuously increasing, and the 
therapeutic effects of agonists and antagonists of the cannabinoid receptors type 1 and 2 
(CB1R and CB2R) have been proposed for the treatment of several human disorders. This 
has been the result of several preclinical and clinical observations in which interactions 
with the cannabinoid receptors seem to alter molecular pathways that are responsible for 
the development of the diseases [29]. CBD is a potential candidate for clinical use thanks 
to its notable lack of psychotropic action and to its remarkable tolerability profile in hu-
mans [30].  
CBD was identified by Adams et al. at the University of Illinois in 1940 but its struc-
ture was not completely clarified until the 1960s by Mechoulam et al. [3]. Up until now, 
the mechanisms of action of CBD are not totally known. It has been determined that CBD 
modulates central nervous system (CNS) receptors such as CB1R (negative allosteric mod-
ulator), CB2R, peroxisome proliferator-activated receptor-gamma (PPARγ), serotonin 1A 
receptor (5-HT1A), transient receptor potential cation channel subfamily V member 1 
(TRPV1) and G protein-coupled receptor 55 (GPR55). CBD may antagonize CB1R receptor 
function by negative allosteric modulation of the orthosteric receptor site [31]. Regarding 
CB2R receptor, although CBD is a weak agonist of this receptor [32] it has been described 
that its activation could provide an anti-inflammatory and anti-oxidative effects [33]. Fur-
thermore, CBD may act as an inverse agonist that could explain in part its anti-inflamma-
tory properties inhibiting immune cell migration [34,35]. In vitro assays have shown that 
CBD is a weak agonist of PPARγbut in vivo assays demonstrated that some CBD biolog-
ical activities can be blocked by pharmacological inhibition of PPARγsuggesting that 
some metabolites of CBD may account for its activity of this nuclear receptor [36]. Fur-
thermore, it has been described that CBD causes analgesia in a TRPV1-dependent manner 
and ameliorates anxiety through 5-HT1A receptor [37]. Besides, 5-HT1A receptor activa-
tion is also involved in CBD neuroprotection in in vitro adult and rat newborn models of 
the acute hypoxic-ischemic brain [38]. Likewise, CBD has been described as functional 
antagonist of the GPR55 receptor that can be relevant to explain the anticonvulsant activ-
ity of CBD [39]. 
Clearly, the impact of CBD on the provides many health benefits. Unfortunately, 
most of this evidence to date comes from animal studies and anecdotal human experience, 
since very few well-controlled human studies have been conducted with CBD, although 
this tendency is changing. 
The Endocannabinoid System 
Due to the interest in recreational and medical uses of marijuana, efforts were made 
early in the sixties to identify the major cannabinoids in the cannabis plant [40,41]. These 
attempts resulted in the discovery of Δ9-THC, CBD, and cannabinol (a processing product 
of Δ9-THC) [3,42,43]. Then, using a synthetic radiolabeled Δ9-THC analogue, high-affinity 
binding sites for Δ9-THC in the brain were discovered as the CB1R [44], a G protein-cou-
pled receptor (GPCR). Afterwards, a second G protein-coupled receptor (GPCR) called 
CB2R was identified outside the CNS, mainly in the immune system [45]. As a result, the 
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cloning and identification of the two main cannabinoid receptors led to isolation of en-
dogenous CB1R and CB2R ligands and the discovery of the endocannabinoid system 
(ECS). The lipids anandamide (N-arachidonoylethanolamide or AEA) and 2-arachi-
donoylglycerol (2-AG), identified in the brain and intestinal tissues, were shown to acti-
vate both receptors with high affinity and as consequence these lipids were named endo-
cannabinoids. The levels of these endocannabinoids is regulated by enzymes, including 
fatty acid amide hydrolase (FAAH) [46] and monoacylglycerol lipase (MAGL) [47], that 
metabolize AEA and 2-AG, respectively. To partly explain their multipronged bioactivi-
ties, exogenous and endogenous cannabinoids also interact with non-cannabinoid recep-
tors as described above for CBD [48].  
Modifications in the ECS are frequently observed in neurological diseases [49] and 
genetic and pharmacological changes of this system in animal models suggest a major role 
for this system in neurodegenerative disorders and demyelinating diseases [50,51]. The 
ECS is a complex system due to the promiscuity of mediators and its interactions with 
other metabolic pathways. The regulation of the ECS components alters the endocanna-
binoid-related system, known as the endocannabidiome (eCBome). This complicated sys-
tem presents a challenge for the discovery of novel bioactive molecules inspired in endo-
cannabinoid and also suggests new chances for the utilization of non-psychotropic can-
nabinoids such as CBD and derivatives of CBD, which frequently modulate several eC-
Bome proteins. In addition, lifestyle, including the lipid dietary component, habits, and 
environment are suggested to have an impact on the eCBome, which seems to be relevant 
in many physiological and pathological conditions [29,52].  
3. Demyelinating Diseases 
Myelin is believed to be generated in early gnathostomes by a glial precursor, which 
later produce the different Schwann cell (SC) and oligodendrocyte lineages [53,54]. In fact, 
the global organization of myelinated axons is similar in the central nervous system (CNS) 
and peripheral nervous system (PNS), regarding their functions in saltatory transmission. 
However, Schwann cells and oligodendrocytes present considerable variations in the de-
velopment and formation of myelin. In line with this, demyelinating diseases are limited 
to those involving PNS myelinated fibers or CNS fibers (Figure 1). 
 
Figure 1. Demyelinating diseases. 
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The myelin disorders can be categorized into several categories according to their 
etiologies: demyelination associated to inflammation, demyelination associated to virus, 
loss of myelin produced by metabolic imbalances, loss of myelin due to hypoxic-ischemic 
conditions and demyelination caused by brain injury. Most of the different categories 
overlap in pathogenesis but this organization may be helpful to establish a diagnosis. The 
prognosis of these diseases is generally difficult, and no curative treatment is currently 
available. 
Several diseases involving significant injury to axons and glial cells, especially SC in 
the PNS, are classified as peripheral demyelinating diseases (PDD) [55]. Schwann cells, 
which are derived from the neural crest, represent the main glial cells in peripheral nerves. 
The development of SC happens through different embryonic and postnatal periods, 
which are strictly controlled by several cellular signaling pathways. Initially, the undiffer-
entiated SC matures into either myelinating or non-myelinating SC and covers around 
axons, thus constituting the process named myelination [56]. The myelin sheath is com-
posed of various coats of lipids and lipoprotein plasma membranes of SC which are ar-
ranged around the axon of neurons [57]. In PNS, the demyelination process involves the 
damage of the myelin sheath due to the injury on SC [58]. Currently, there are no con-
sistent biomarkers for PNS-associated disorders and the diagnosis is based on several 
studies such as electrophysiological and cerebrospinal fluid (CSF) analysis. PDD can be 
classified in two main groups: Acquired Demyelinating Diseases and Inherited Demye-
linating Diseases (Figure 1).  
The first group comprises four main type of disorders such as Guillain-Barre Syn-
drome (GBS), chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), anti-
myelin associated glycoprotein (MAG) neuropathy and polyneuropathy, organomegaly, 
endocrinopathy, m protein and skin changes (POEMS) syndrome. GBS is a severe idio-
pathic autoimmune demyelinating disease associated to acute ascending neuromuscular 
palsy [59]. A high percentage of GBS cases have been related to autoantibodies related 
with several bacterial and viral infections [60–62]. Emerging information suggests that 
acute respiratory syndrome coronavirus-2 (SARS-CoV-2 or COVID-19) can cause GBS and 
several neurological autoimmunity-related diseases requiring attention for quick diagnos-
tic and treatment [63]. MAG neuropathy is caused by circulating monoclonal antibodies 
towards the human natural killer-1 epitope. This epitope is expressed on adhesion mole-
cules present in peripheral nerves such as the glycoprotein MAG. A low expression of 
MAG affects the myelin sheath structure and axonal function. This progressive disease 
causes mild to moderate distal muscle fragility, with gradual sensory ataxia and recurrent 
tremors [64]. CIDP is associated with a gradual loss of sensorimotor functions [65]. There 
are several effective treatments based on immunoglobulin, corticosteroids, and plasma 
exchange treatments, but long-lasting treatments are needed. Regarding POEMS syn-
drome, this is an unusual paraneoplastic syndrome with demyelinating neuropathy pro-
duced by a disorder related to plasma cell proliferation. The association of vascular endo-
thelial growth factor (VEGF) with POEMS syndrome is very effective in clinical diagnosis 
as accurate biomarker and monitoring responses to treatment. POEMS patients present 
high serum level of VEGF, although low levels are described upon effective treatment [66]. 
The second group of hereditary demyelinating diseases include Charcot Marie tooth 
disease (CMT). Although CMT is an uncommon inherited neurological disease, it is the 
major disorder that affects the peripheral nerves. CMT patients, despite their genetic het-
erogeneity, typically present an indolent, length-dependent, sensorimotor polyneuropa-
thy [67].  
Currently, synthetic drugs and natural products are used for the management of 
PDD. Nevertheless, these diseases remain misdiagnosed due to the absence of solid bi-
omarkers and disease safe-diagnostic criteria. Therefore, the search for new therapies and 
accurate biomarkers are essential to address this type of neuropathic disease [68].  
Demyelinating disorders of the CNS have different etiologies and are divided into 
primary, such as MS and other idiopathic inflammatory-demyelinating diseases (IIDDs), 
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and secondary, such as infective, ischemic, metabolic, or toxic diseases (Figure 1). These 
CNS demyelinating diseases comprise MS and its acute variant Marburg disease, also 
neuromyelitis optica (NMO), Balo’s concentric sclerosis, acute disseminated encephalo-
myelitis (ADEM), and ADEM’s hyperacute variant, acute hemorrhagic leukoencephalitis 
(AHL) (Figure 1). The term IIDD includes several CNS disorders that are classified ac-
cording to their severity, clinical progression, and lesioned zone, as well as their patho-
logical outcomes. The spectrum of diseases involves monophasic, multiphasic, and pro-
gressive disorders. Aggressive types of IIDD include a plethora of disorders that share the 
symptomatology, an acute clinical course, and atypical outcomes on magnetic resonance 
imaging (MRI). Marburg disease is the classic fulminant IIDD, but it is extremely rare. 
Baló’s concentric sclerosis, which is considered a variant of MS and ADEM, can also ap-
pear with acute attacks [69].  
MS is characterized by inflammation-related injury, principally to myelin structure 
and composition from nerves in the brain (including optic nerves) and spinal cord, caus-
ing axonal damage and neurodegeneration. The most frequent forms of MS are the relaps-
ing-remitting (RR) and secondary progressive (SP) forms, although it can also present a 
progression from onset (primary progressive (PP). The presentation of demyelinating le-
sions distributed in time and space are critical in the clinical diagnosis of MS. In addition 
to the neurological symptoms, lesions consistent with MS determined by MRI, along with 
presentation of oligoclonal bands in CSF and findings of abnormal visual evoked poten-
tials, are proposed to provide an accurate diagnosis [70]. Neuromyelitis optica spectrum 
disorder (NMOSD) and myelin oligodendrocyte glycoprotein (MOG) antibody (Ab)-asso-
ciated disease are also inflammatory CNS demyelinating disorders although clinically and 
pathologically they differ from MS and are far less common. NMO has been identified as 
a disease distinct from MS due to the identification of an NMO-specific autoantibody di-
rected against aquaporin-4 (AQP4-Ab), the major water channel in the CNS [71].  
Among the infectious inflammatory demyelinating disorders, progressive multifocal 
leukoencephalopathy (PML) is an aggressive CNS infection caused by JC virus (JCV). The 
disease is triggered by a JCV that selectively damages the oligodendrocytes, causing de-
myelination. Therapy with monoclonal antibody treatment or other immunomodulatory 
drugs, generally applied to MS patients, has also been used for PML treatment [72]. 
Traumatic brain injury (TBI) and stroke are major pathologies which result in demy-
elination. The neurovascular unit (NVU) is constituted by neurons, endothelial cells, 
smooth muscle cells, pericytes, astrocytes, and microglia [73]. This NVU is affected by 
secondary injuries after TBI and suffer alterations such as a reduction of blood–brain per-
fusion with adverse effects on the correct function of the neurons [74]. During the past 
decades, cerebrovascular dysfunction has been associated with a poor prognostic out-
come. In addition, alterations in the structure of the blood-brain barrier (BBB) trigger 
edema generation with interference in the brain homeostasis. This alteration exacerbates 
the secondary injury processes including excitotoxicity and inflammation. For these rea-
sons, TBI has been considered a chronic brain disease with molecular alterations in the 
BBB after the initial injury [75]. This long-term alteration of the blood-brain barrier could 
be responsible of premature aging of the brain after TBI [75,76]. Research on animal mod-
els have shown that cannabinoids targeting CB2R after TBI improve neurobehavioral man-
ifestations and memory tests and the neurological insufficiency, and diminish motor def-
icit through downregulation of proinflammatory markers. Furthermore, the modulation 
of cannabinoid system reduces oedema generation and BBB permeability, avoiding neu-
ronal cell death and upregulating the levels of adherence junction proteins (reviewed in 
[77]). Moreover, PPARγ seems to be another interesting target to prevent neuroinflamma-
tion and demyelination in TBI [78].  
At present, advancement has been made in identifying the pathogenesis of demye-
linating disorders, but we have to discover their origin or a therapeutic treatment for these 
debilitating diseases that affect millions of young adults around the world. The develop-
ment of new therapies for the treatment of these diseases remains a challenge. Indeed, the 
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support of the beneficial potential of cannabinoids, especially CBD, for the control of 
pathological events related to these diseases is increasing. 
4. Cannabidiol and Demyelinating Diseases 
During the past decade, the therapeutic potential of cannabinoids for treating demy-
elinating diseases, specifically MS, has been well-studied. It is now established that CBD 
and various CBD-derivatives confer neuroprotective effects and attenuate the inflamma-
tory process in several demyelinating animal models [19,20,25,79]. For instance, the im-
pact of CBD has been determined in hypoxic-ischemic immature brain. CBD, at micromo-
lar concentrations, reduces the levels of inflammatory markers such as interleukin-6 (IL-
6), tumor necrosis factor-α (TNF-α), cyclooxygenase-2 (COX-2), and inducible nitric oxide 
synthase (iNOS), through activation of CB2R and A2A receptors [80,81]. Regarding A2A 
receptors, it has been described that CBD increases adenosine signaling inhibiting adeno-
sine uptake [82]. 
Currently the search for new remyelinating therapies is focused principally on iden-
tifying the factors that promote repair of the myelin sheath. Demyelinating diseases share 
as a common feature the principal pathogenic process that targets the myelin sheath. This 
neuronal covering allows proper conduction of the nerve impulses. MS is characterized 
in particular by a decrease in the number of oligodendrocytes producing myelin in the 
CNS and by progressive axonal deterioration. As it occurs in most demyelinating diseases, 
damage of the myelin sheath triggers regeneration mechanisms, a process named remye-
lination. Oligodendrocytes responsible for production of mature myelin are derived dur-
ing postnatal development from immature cells named oligodendrocyte progenitor cells 
(OPCs). OPCs stay in the adult brain and produce new mature oligodendrocytes when 
the myelin is injured. The beneficial role of CBD against injury to OPCs mediated by the 
immune system has been described. Indeed, cells treated with CBD present less oxidative 
stress avoiding the generation of reactive oxygen species. Furthermore, the treatment of 
OPC with CBD prevented apoptosis by mechanisms independent from CB1R, CB2R, 
TRPV1 or PPARγ receptors [13]. OPCs have remarkable metabolic conditions during de-
velopment because they can differentiate to generate myelin segments, indicating they 
need a satisfactory blood supply. However, processes that coordinate myelination and 
angiogenesis must be better defined. It has been described that Hypoxia-Inducible Factor 
(HIF) is an important regulator of postnatal myelination. HIF-1α activation may play a 
role in the inflammatory and the remitting phases of MS [83]. Moreover, activation of the 
HIF pathway may also be associated to neuronal protection and remyelination [84]. Thus, 
we have described that VCE-004.8, a synthetic aminoquinone derivative of cannabidiol, 
could be a potential drug to treat MS by regulating the immune response and supporting 
neuroprotection and axonal regeneration through activation of the hypoxia-inducible fac-
tor pathway. Furthermore, this novel synthetic cannabinoid, which also acts as a dual 
PPARγ and CB2R agonist, presents potent anti-inflammatory activity [25]. 
Neonatal hypoxia-ischemia (HI), which causes myelination disorders and is related 
to cerebral palsy, presents a complex pathophysiology which includes oxidative stress, 
excitotoxicity, and severe inflammatory response [85,86]. Due to this altered environment, 
oligodendrocyte progenitors are particularly sensitive. Thus, OPC injury is increased in 
the brain, both in animal models and human newborns after HI damage [87] which even-
tually leads to hypomyelination [88]. The protective role of CBD after HI injury in new-
born animals has been described in neuronal and glial cells [89]. 
MS, as well as other demyelinating diseases, presents many of the characteristics of 
autoimmune disorder with rupture of the BBB. The BBB is an extraordinary composition 
of endothelial cells, pericytes, which are enclosed and supported by astrocytes and peri-
vascular macrophages. In pathological circumstances, peripheral lymphocytes are acti-
vated and infiltrate the CNS to trigger an immune response injuring myelin and axons. In 
an experimental model of MS, the Theiler’s murine encephalomyelitis virus-induced de-
myelinating disease, it has been demonstrated that CBD ameliorates the symptomatology 
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of the disease. It has been shown that intraperitoneal treatment with CBD reduces the 
extravasation of leukocytes from the systemic circulation by downregulating the expres-
sion of several chemokines as well as by decreasing microglia activation [90]. Further-
more, the effect of CBD on BBB permeability has been determined by using human brain 
microvascular endothelial cells and human astrocyte co-cultures as a BBB model. In this 
model, CBD restored the BBB permeability produced by oxygen-glucose deprivation 
(OGD). Treatment was more efficient when it was administered prior to OGD, but posi-
tive results were detected up to two hours into reperfusion. The protective effect was de-
pendent on PPARγ and relatively reduced by a 5-HT1A receptor antagonist but was in-
dependent of CB1R, CB2R, TRPV1 or Adenosine A2A receptors [91]. 
During the past few decades, our understanding about the loss of myelin after stroke 
and TBI has increased. Previous research on these pathologies highlighted changes in neu-
ronal cells within the gray matter. Recently, several studies have shown the same im-
portance of the white matter integrity in long-term recovery. Demyelination following 
brain injury causes long-term sensory, motor, and cognitive insufficiencies due to the 
adult brain’s low capability to regenerate oligodendrocyte cells and the restoration of ax-
onal myelin. New molecules that control the process of remyelination may offer novel 
therapies to restore white matter integrity and improve long-term neurological improve-
ment in stroke and TBI patients. In addition, it has been shown that treatment with oral 
CBD oil restored behavioral dysfunctions and normalized the cortical biochemical 
changes associated with TBI. Therefore, CBD has been proposed as a pharmacological tool 
to improve neurological dysfunctions triggered by the trauma [92]. Furthermore, several 
studies have shown that short-term treatment with CBD in a mouse model of brain injury, 
such as bilateral common carotid artery occlusion (BCCAO), is capable of improving mo-
tor and cognitive disability by activating a complex mechanism related with an increase 
in hippocampal levels of brain-derived neurotrophic factor (BDNF) and microtubule-as-
sociated protein 2 (MAP-2) proteins, resulting in stimulation of neurogenesis. Because of 
these effects, the treatment with CBD ameliorated neuroinflammation and neuronal death 
in the hippocampal zone [9,93]. 
5. Medicinal Chemistry of Synthetic and Natural Derivatives of Cannabidiol  
Of the over one hundred phytocannabinoids discovered in Cannabis sativa, seven 
have been categorized as CBD-type compounds, including CBD [94,95]. All of them pre-
sent the same configuration as CBD. Among these natural analogs, cannabidiolic acid 
(CBDA) and cannabidivarinic acid (CBDVA-C3), which are C30-carboxylic derivatives, 
have been isolated. Moreover, cannabidiorcol (CBD-C1), cannabidiol-C4 and cannabidi-
varin (CBDV), which vary from CBD by the length of their C40-side chain, have been 
identified. Finally, cannabidiol monomethyl ether (CBDM), the C60-methoxy CBD analog, 
has also been isolated from the plant. Although these natural CBD derivatives present 
potential therapeutic benefits (Table 1), only a few pharmacological studies have been de-
scribed [14–17].  
Because of the favorable therapeutic benefits of CBD in a variety of diseases, synthetic 
CBD derivatives have also been taken into consideration by drug discovery projects, with 
the purpose of improving the potency, efficacy, and/or pharmacokinetic properties of this 
natural cannabinoid. To obtain new synthetic analogs, a series of structural modifications 
such as hydrogenation of CBD produced the dihydro and tetrahydrocannabidiol deriva-
tives H2-CBD and H4-CBD [18]. These molecules have been attributed anti-inflammatory 
properties because of their effects on the generation of reactive oxygen species, nitric ox-
ide, and tumor necrosis factor. Furthermore, the hydroxy-CBD enantiomers, named HU-
446 and HU-465, have shown potential anti-inflammatory effects in a proinflammatory 
model of encephalitogenic T cells (Table 1). Specifically, both HU-446 and HU-465 pre-
vented the production of IL-17, a crucial autoimmune cytokine, from MOG35-55-stimulated 
T(MOG) cells. These data indicated that both CBD derivatives have anti-inflammatory 
effects in autoimmune diseases [19]. 
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The synthesis of dimethylheptyl (DMH) CBD derivatives such as DMH-CBD, HU-
320 [21], and 7-OH-DMH-CBD have been described by Mechoulam and colleagues [96]. 
In the case of DMH-CBD, it was reported that this derivative abolishes the production of 
proinflammatory cytokines and prevents microglia reactivation by generating an adap-
tive cellular response, thus avoiding inflammation and oxidative injury (Table 1). In ad-
dition, DMH-CBD reduced the proliferation of pathogenic activated TMOG cells [20]. For 
such derivative, remarkable benefits such as anti-inflammatory, analgesic, neuroprotec-
tive or antitumor effects have been described, and it has been used as a pharmacological 
tool in many cannabinoid studies supporting the progress in this field [11].  
Finally, other interesting modifications have consisted of changes in the C40-alkyl 
chain with the purpose of improving oral bioavailability, modifications of the resorcinol 
hydroxyl groups, thus generating new molecules (named HU-410, HU-427, and HU-432) 
that present anti-inflammatory activities as reported in the patent literature (Table 1) [22]. 
The development of new quinone derivatives of CBD has also been investigated.  
The first quinone derivative of CBD, named HU331, was described by Mechoulam et 
al. by oxidation of CBD [97] and its antineoplastic activity was reported (Table 1) [23]. 
Quinone-based drugs causing anti-infective and antitumoral effects are frequently ap-
plied in clinical practice, but their use for chronic therapies is not recommended due to 
their reactivity and toxicity. HU-331 is a thiol-trapping compound that generates reactive 
oxygen species (ROS), affects the mitochondria transmembrane potential and causes cy-
totoxicity in primary and transformed cells in vitro [98].  
We have generated a non-thiophilic and chemically stable derivative of a CBD ami-
noquinone (VCE-004.8) that acts as a dual agonist of PPARγ and CB2R. VCE-004.8 does 
not have affinity for the CB1R receptor and presents potent antifibrotic activity in vitro 
and in vivo (Table 1) [24]. Furthermore, we have described that VCE-004.8 also activates 
the HIF pathway. In fact, we have reported that VCE-004.8 stabilizes and activates HIF-
1α and HIF-2α in human microvascular endothelial cells, oligodendrocytes, and microglia 
cells [25]. VCE-004.8 ameliorated neuroinflammation and prevented myelin loss in several 
murine models of MS, such as Experimental autoimmune encephalomyelitis (EAE) and 
Theiler´s virus-induced demyelinating disease [25]. Recently, we have reported that EHP-
101, which is an oral lipidic formulation of VCE-004.8, also had efficacy in EAE and in-
duced remyelination in two demyelination models induced by cuprizone. [28]. Hence, 
EHP-101 could be a promising cannabinoid-derived drug candidate for the treatment of 
different forms of MS. In addition, EHP-101 also demonstrated efficacy in a murine model 
of systemic sclerosis (SSc) [26,27]. EHP-101 is now under evaluation in a Phase II study in 
SSc patients (ClinicalTrials.gov: NCT04166552) and the initiation of a Phase II study in MS 
patients is underway. 
6. Clinical Trials of Cannabidiol Focused on Demyelinating Disorders 
Currently, medicine may be focused on CBD as a new treatment for patients with 
reduced conventional options and medical professionals are often asked about CBD prod-
ucts by patients, family, and patient associations. Due to its minimal toxicity in humans, 
an interesting number of trials have been performed to determine the clinical efficacy of 
CBD in different pathologies. Numerous CBD formulations have been assessed in preclin-
ical studies for various pharmaceutical properties, such as anti-nausea, anti-emetic, anti-
tumor, anti-inflammatory, antidepressant, anti-psychotic, and anti-anxiolytic [10–12,99] 
benefits. Nevertheless, the variation in CBD quality, the type of drug formulations ap-
plied, and the minimal sample sizes compromise the development of these preclinical 
studies.  
As we have previously indicated in this review, to date the FDA has approved three 
CBD- and Δ9-THC-based medicines. Dronabinol (Marinol, Syndros) which is a synthetic 
form of THC in an oily base, administered to stimulate appetite in AIDS patients and for 
the improvement of nausea and vomiting associated with cancer chemotherapy. Nabilone 
(Cesamet) is another Δ9−THC analog for the treatment of nausea in patients undergoing 
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chemotherapy. Cannabidiol oral solution (Epidiolex) is authorized in the USA as therapy 
of two severe rare childhood epilepsy disorders (Dravet syndrome and Lennox-Gastault 
syndrome). A fourth medication, nabiximols (Sativex), a combination of Δ9−THC and 
CBD, is sold legally in more than ten countries including Canada, Mexico, and parts of 
Europe, for the treatment of muscle spasticity and neuropathic pain in multiple sclerosis, 
and the FDA recently recognized an Investigational New Drug application for nabiximols. 
This aromatized water-ethanol oral-mucosal spray was created to offer a simple delivery 
system. Specifically, this method of dispensation allows rapid entry to the circulation 
through the oral mucosa with an extremely rapid plateau of plasma concentration, pre-
venting the complications of the gastrointestinal route. Furthermore, it has been shown 
that co-administration of CBD to Δ9-THC counteracts the undesirable effects of Δ9-THC 
alone [100].  
Until now there are about 2,500 clinical trials focused on demyelinating disorders 
and among them only 30 studies have been related to the benefits of cannabis or canna-
binoids. In fact, there are 19 clinical trials that address the effect of CBD in demyelinating 
disorders, specifically in MS. Medicinal cannabis has been researched as potential therapy 
for multiple sclerosis symptomatology, such as pain and spasticity [101]. During the first 
10 years of initial MS diagnosis, up to 80 percent of patients are affected by moderate 
spasticity and the numbers of affected patients rises over time [102,103]. The study called 
”The Cannabinoids for Treatment of Spasticity and Other Symptoms Related to Multiple Sclerosis 
(CAMS)“ was a major randomized trial that explored spasticity in more than 600 MS pa-
tients. This study did not observe changes in the Ashworth Spasticity Scale between either 
oral cannabis extract contrasted with placebo after 15 weeks. However, objective improve-
ment in mobility and pain suggested cannabinoids might be clinically beneficial [104]. 
Many studies have investigated the pharmacological properties of cannabinoids in 
demyelinating diseases such as MS. In fact, most of the trials have been executed using 
Sativex which is suggested as a second line therapy for spasticity in MS patients who do 
not respond to other anti-spasticity treatment and who experienced clinically remarkable 
improvement in symptoms associated to spasticity during the onset of the trial. Since the 
first reported study in 2003, when an initial controlled study determined that cannabis 
extracts could improve intractable neurogenic symptoms [105,106], and during the last 
decade, several clinical trials have evaluated the efficacy of Sativex as a supplementary 
treatment for symptomatology recovery in patients with MS-related spasticity and neuro-
pathic pain.  
In 2010, a meta-analysis of the effectiveness and security of nabiximols on spasticity 
in 666 MS patients showed remarkable superior percentage of treated patients as respond-
ers and treated patients also reported remarkable improvements [107]. In the same year, 
a double-blind, randomized, placebo-controlled, parallel-group study of nabiximols was 
performed in subjects with symptoms of spasticity due to MS. This randomized controlled 
trial studied the treatment effects in 337 subjects for 15 weeks and no important improve-
ment in the mean spasticity numerical rate scale (NRS) was observed in intent-to-treat 
(ITT) analysis but responder per protocol (PP) analyses confirmed that nabiximols treat-
ment caused an important decrease in treatment-resistant spasticity, in patients with pro-
gressive MS and severe spasticity [108]. Later, Novotna et al., published the results de-
rived from a randomized, double-blind, placebo-controlled, parallel-group, enriched-de-
sign study of nabiximols, as add-on therapy, in MS subjects with refractory spasticity. In 
this trial, 241 randomized patients received treatment with nabiximols, as add-on therapy, 
in a single-blind manner for 28 days, after which those showing positive effects in spas-
ticity of ≥ 20% progressed to 84-days randomized, placebo-controlled phase. ITT analysis 
showed an important significant variation positive for nabiximols treatment [109]. In 2014, 
the results derived from the first Phase III placebo-controlled study of the efficacy of the 
nabiximols to improve central neuropathic pain (CNP), which occurs in many MS pa-
tients, were published. More than 300 subjects were randomized to Phase A (167 received 
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nabaximols and 172 received placebo). Of those who finished Phase A, 58 started the ran-
domized-withdrawal phase. The results of this research were ambiguous, with contradic-
tory conclusions in the study [110]. In 2014, a multicenter, non-interventional study called 
MOVE-2 showed the effect of nabiximols in 276 patients [111]. After one month, nabixi-
mols improved resistant MS spasticity (MSS) in 74.6% of patients. After three months, 
55.3% of subjects had persisted to receive nabiximols and the mean NRS score had de-
creased by 25% from baseline. This study MOVE-2 was prolongated for 12 months and 52 
patients were incorporated to the effectiveness analysis. The mean spasticity NRS reduced 
considerably from 6.0 ± 1.8 at baseline to 4.8 ± 1.9 after the first 30 days and remained on 
4.5 ± 2.0 after 12 months [112]. These data confirmed the long-term efficacy and tolerability 
of nabiximols for the therapy of resistant MSS in clinical. 
Recently, Marinelli et al. proposed a novel study to identify if nabiximols could be 
useful ameliorating spasticity in stroke and to investigate its tolerability and security by 
accurate cardiovascular monitoring. The study will recruit 50 patients with spasticity fol-
lowing stroke to be dosed with nabiximols in a double-blind placebo-controlled cross-
over study [113]. Finally, in 2019 the results derived from the study named SAVANT were 
published, evaluating the effects of nabiximols as add-on therapy versus optimized first 
line antispastics in resistant MS spasticity. In this double-blind, placebo-controlled ran-
domized clinical trial of 191 patients who entered Phase A, 106 were randomized in Phase 
B to receive add-on nabiximols spray (n = 53) or placebo (n = 53). The percentage of clini-
cally relevant responders after 12 weeks was significantly superior with nabiximols than 
placebo [114]. 
At present, data indicates that cannabidiol and some derivatives have a remarkable 
role in the modulation of myelinating processes, and it has been suggested as a promising 
approach in the treatment of demyelinating diseases. Although serious advances are be-
ing made in the development of new cannabidiol derivative drugs and therapeutic targets, 
the collaboration of researchers and pharmaceutical companies is needed to achieve suc-
cessful outcomes. 
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Abbreviations 
2-AG 2-arachidonoylglycerol 
ADEM Acute Disseminated Encephalomyelitis  
AEA Anandamide 
AHL Acute Hemorrhagic Leukoencephalitis 
AIDS Acquired Immunodeficiency Syndrome 
BBB Blood-Brain Barrier 
BCCAO Bilateral Common Carotid Artery Occlusion  
BDNF Brain-Derived Neurotrophic Factor 
CB1R Cannabinoid receptor type 1 
CB2R Cannabinoid receptor type 2 
CBD Cannabidiol 
CBDA Cannabidiolic Acid  
CBDM Cannabidiol Monomethyl Ether  
CBDV Cannabidivarin  
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CBDVA Cannabidivarinic Acid 
CIDP Chronic Inflammatory Demyelinating Polyradiculoneuropathy 
CMT Charcot Marie Tooth Disease 
CNP Central Neuropathic Pain 
CNS Central Nervous System 
COX-2 Cyclooxygenase-2  
CSF Cerebrospinal Fluid 
EAE Experimental Autoimmune Encephalomyelitis 
eCBome Endocannabidiome  
ECS Endocannabinoid System 
FAAH Fatty Acid Amide Hydrolase  
FDA Food and Drug Administration 
GBS Guillain-Barre Syndrome 
GPCR G protein-coupled receptor  
GPR55 G protein-coupled receptor 55  
HI Hypoxia-Ischemia 
HIF Hypoxia-Inducible Factor 
IIDDs Idiopathic Inflammatory-Demyelinating Diseases  
IL-6 Interleukin-6 
iNOS Inducible Nitric Oxide Synthase 
MAG Anti-Myelin Associated Glycoprotein 
MAGL Monoacylglycerol Lipase  
MAP-2 Microtubule-Associated Protein 2  
MOG Myelin Oligodendrocyte Glycoprotein 
MRI Magnetic Resonance Imaging 
MS Multiple Sclerosis 
NMO Neuromyelitis Optica 
NMOSD Neuromyelitis Optica Spectrum Disorder  
NRS Numerical Rate Scale 
NVU Neurovascular Unit 
OGD Oxygen-Glucose Deprivation 
OPCs Oligodendrocyte Progenitor Cells 
PDD Peripheral Demyelinating Diseases 
PML Progressive Multifocal Leukoencephalopathy 
PNS Peripheral Nervous System 
POEMS Polyneuropathy, Organomegaly, Endocrinopathy, M protein and Skin 
changes Syndrome 
PP Primary Progressive 
PPARγ Peroxisome Proliferator-Activated Receptor-Gamma  
ROS Reactive Oxygen Species 
RR Relapsing-Remitting 
SC Schwann Cell 
SP Secondary Progressive 
TBI Traumatic Brain Injury 
TNF-α Tumor Necrosis Factor-α  
TRPV1 Transient Receptor Potential Cation Channel Subfamily V Member 1  
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